{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:19:15Z","timestamp":1792588755494,"version":"4.5.0"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer is one of the three leading causes of death worldwide. Even after successful therapy and achieving remission, the risk of relapse often remains. In this context, dormant residual cancer cells in secondary organs such as the bone marrow constitute the cellular reservoir from which late tumor recurrences arise. This dilemma leads the term of minimal residual disease, which reflects the presence of tumor cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological signs of metastasis or residual tumor cells left behind after therapy that eventually lead to local recurrence. Disseminated tumor cells have the ability to survive in a dormant state following treatment and linger unrecognized for more than a decade before emerging as recurrent disease. They are able to breakup their dormant state and to readopt their proliferation under certain circumstances, which can finally lead to distant relapse and cancer-associated death. In recent years, extensive molecular and genetic characterization of disseminated tumor cells and blood-based biomarker has contributed significantly to our understanding of the frequency and prevalence of tumor dormancy. In this article, we describe the clinical relevance of disseminated tumor cells and highlight how latest advances in different liquid biopsy approaches can be used to detect, characterize, and monitor minimal residual disease in breast cancer, prostate cancer, and melanoma patients.<\/jats:p>","DOI":"10.1007\/s10555-022-10075-x","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T10:04:57Z","timestamp":1672999497000},"page":"161-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors"],"prefix":"10.1007","volume":"42","author":[{"given":"Isabel","family":"Heidrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Deitert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"issue":"12","key":"10075_CR1","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis, G. J., Heuser, M., Freeman, S., Bene, M. C., Buccisano, F., Cloos, J., et al. (2018). Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party. Blood, 131(12), 1275\u20131291. https:\/\/doi.org\/10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"issue":"9","key":"10075_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3793","volume":"14","author":"MS Sosa","year":"2014","unstructured":"Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014). Mechanisms of disseminated cancer cell dormancy: An awakening field. Nature Reviews Cancer, 14(9), 611\u2013622. https:\/\/doi.org\/10.1038\/nrc3793","journal-title":"Nature Reviews Cancer"},{"issue":"4","key":"10075_CR3","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabieres","year":"2021","unstructured":"Alix-Panabieres, C., & Pantel, K. (2021). Liquid biopsy: From discovery to clinical application. Cancer Discovery, 11(4), 858\u2013873. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1311","journal-title":"Cancer Discovery"},{"issue":"6","key":"10075_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJM200302063480620","volume":"348","author":"RM MacKie","year":"2003","unstructured":"MacKie, R. M., Reid, R., & Junor, B. (2003). Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. New England Journal of Medicine, 348(6), 567\u2013568. https:\/\/doi.org\/10.1056\/NEJM200302063480620","journal-title":"New England Journal of Medicine"},{"issue":"7171","key":"10075_CR5","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","volume":"450","author":"CM Koebel","year":"2007","unstructured":"Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., et al. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450(7171), 903\u2013907. https:\/\/doi.org\/10.1038\/nature06309","journal-title":"Nature"},{"issue":"11","key":"10075_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology, 3(11), 991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991","journal-title":"Nature Immunology"},{"issue":"6","key":"10075_CR7","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1172\/JCI42002","volume":"120","author":"J Eyles","year":"2010","unstructured":"Eyles, J., Puaux, A. L., Wang, X., Toh, B., Prakash, C., Hong, M., et al. (2010). Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. The Journal of Clinical Investigation, 120(6), 2030\u20132039. https:\/\/doi.org\/10.1172\/JCI42002","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10075_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","volume":"13","author":"Y Husemann","year":"2008","unstructured":"Husemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., et al. (2008). Systemic spread is an early step in breast cancer. Cancer Cell, 13(1), 58\u201368. https:\/\/doi.org\/10.1016\/j.ccr.2007.12.003","journal-title":"Cancer Cell"},{"issue":"7634","key":"10075_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature20785","volume":"540","author":"H Hosseini","year":"2016","unstructured":"Hosseini, H., Obradovic, M. M. S., Hoffmann, M., Harper, K. L., Sosa, M. S., Werner-Klein, M., et al. (2016). Early dissemination seeds metastasis in breast cancer. Nature, 540(7634), 552\u2013558. https:\/\/doi.org\/10.1038\/nature20785","journal-title":"Nature"},{"issue":"7","key":"10075_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41588-019-0423-x","volume":"51","author":"Z Hu","year":"2019","unstructured":"Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J. A., Scott Shaffer, J., et al. (2019). Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 51(7), 1113\u20131122. https:\/\/doi.org\/10.1038\/s41588-019-0423-x","journal-title":"Nature Genetics"},{"issue":"10","key":"10075_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3390\/cancers11101569","volume":"11","author":"ML De Angelis","year":"2019","unstructured":"De Angelis, M. L., Francescangeli, F., & Zeuner, A. (2019). Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: new challenges and therapeutic opportunities. Cancers (Basel), 11(10), 1569. https:\/\/doi.org\/10.3390\/cancers11101569","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10075_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","volume":"16","author":"K Pantel","year":"2010","unstructured":"Pantel, K., & Alix-Panabieres, C. (2010). Circulating tumour cells in cancer patients: Challenges and perspectives. Trends in Molecular Medicine, 16(9), 398\u2013406. https:\/\/doi.org\/10.1016\/j.molmed.2010.07.001","journal-title":"Trends in Molecular Medicine"},{"issue":"6024","key":"10075_CR13","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer, C. L., & Weinberg, R. A. (2011). A perspective on cancer cell metastasis. Science, 331(6024), 1559\u20131564. https:\/\/doi.org\/10.1126\/science.1203543","journal-title":"Science"},{"issue":"5","key":"10075_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7150\/jca.17648","volume":"8","author":"M Wang","year":"2017","unstructured":"Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., et al. (2017). Role of tumor microenvironment in tumorigenesis. Journal of Cancer, 8(5), 761\u2013773. https:\/\/doi.org\/10.7150\/jca.17648","journal-title":"Journal of Cancer"},{"issue":"1","key":"10075_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201303698","volume":"7","author":"SA Joosse","year":"2015","unstructured":"Joosse, S. A., Gorges, T. M., & Pantel, K. (2015). Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med, 7(1), 1\u201311. https:\/\/doi.org\/10.15252\/emmm.201303698","journal-title":"EMBO Mol Med"},{"key":"10075_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcancer.2021.02.001","volume":"78","author":"S Werner","year":"2022","unstructured":"Werner, S., Heidrich, I., & Pantel, K. (2022). Clinical management and biology of tumor dormancy in breast cancer. Seminars in Cancer Biology, 78, 49\u201362. https:\/\/doi.org\/10.1016\/j.semcancer.2021.02.001","journal-title":"Seminars in Cancer Biology"},{"issue":"4","key":"10075_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s12276-020-0423-z","volume":"52","author":"SY Park","year":"2020","unstructured":"Park, S. Y., & Nam, J. S. (2020). The force awakens: Metastatic dormant cancer cells. Experimental & Molecular Medicine, 52(4), 569\u2013581. https:\/\/doi.org\/10.1038\/s12276-020-0423-z","journal-title":"Experimental & Molecular Medicine"},{"key":"10075_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.08.003","volume":"21\u201322","author":"S Blatter","year":"2015","unstructured":"Blatter, S., & Rottenberg, S. (2015). Minimal residual disease in cancer therapy\u2013small things make all the difference. Drug Resist Updat, 21\u201322, 1\u201310. https:\/\/doi.org\/10.1016\/j.drup.2015.08.003","journal-title":"Drug Resist Updat"},{"issue":"11","key":"10075_CR19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7(11), 834\u2013846. https:\/\/doi.org\/10.1038\/nrc2256","journal-title":"Nature Reviews Cancer"},{"issue":"6","key":"10075_CR20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-18-3437","volume":"79","author":"T Saleh","year":"2019","unstructured":"Saleh, T., Tyutyunyk-Massey, L., & Gewirtz, D. A. (2019). Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy. Cancer Research, 79(6), 1044\u20131046. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3437","journal-title":"Cancer Research"},{"key":"10075_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Coppe","year":"2010","unstructured":"Coppe, J. P., Desprez, P. Y., Krtolica, A., & Campisi, J. (2010). The senescence-associated secretory phenotype: The dark side of tumor suppression. Annual Review of Pathology: Mechanisms of Disease, 5, 99\u2013118. https:\/\/doi.org\/10.1146\/annurev-pathol-121808-102144","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"issue":"2","key":"10075_CR22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","volume":"39","author":"E Dhimolea","year":"2021","unstructured":"Dhimolea, E., de Matos Simoes, R., Kansara, D., Al\u2019Khafaji, A., Bouyssou, J., Weng, X., et al. (2021). An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell, 39(2), 240-256e211. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.002","journal-title":"Cancer Cell"},{"issue":"1","key":"10075_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"SK Rehman","year":"2021","unstructured":"Rehman, S. K., Haynes, J., Collignon, E., Brown, K. R., Wang, Y., Nixon, A. M. L., et al. (2021). Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell, 184(1), 226-242 e221. https:\/\/doi.org\/10.1016\/j.cell.2020.11.018","journal-title":"Cell"},{"issue":"1","key":"10075_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12964-016-0155-9","volume":"15","author":"R Greil","year":"2017","unstructured":"Greil, R., Hutterer, E., Hartmann, T. N., & Pleyer, L. (2017). Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. Cell Communication and Signaling: CCS, 15(1), 5. https:\/\/doi.org\/10.1186\/s12964-016-0155-9","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"13","key":"10075_CR25","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-13-3456","volume":"74","author":"D Raha","year":"2014","unstructured":"Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., et al. (2014). The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Research, 74(13), 3579\u20133590. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3456","journal-title":"Cancer Research"},{"issue":"11","key":"10075_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.tcb.2018.06.008","volume":"28","author":"AR Nobre","year":"2018","unstructured":"Nobre, A. R., Entenberg, D., Wang, Y., Condeelis, J., & Aguirre-Ghiso, J. A. (2018). The different routes to metastasis via hypoxia-regulated programs. Trends in Cell Biology, 28(11), 941\u2013956. https:\/\/doi.org\/10.1016\/j.tcb.2018.06.008","journal-title":"Trends in Cell Biology"},{"issue":"2","key":"10075_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/ncb3465","volume":"19","author":"G Fluegen","year":"2017","unstructured":"Fluegen, G., Avivar-Valderas, A., Wang, Y., Padgen, M. R., Williams, J. K., Nobre, A. R., et al. (2017). Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nature Cell Biology, 19(2), 120\u2013132. https:\/\/doi.org\/10.1038\/ncb3465","journal-title":"Nature Cell Biology"},{"issue":"6193","key":"10075_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.1253533","volume":"345","author":"M Yu","year":"2014","unstructured":"Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., et al. (2014). Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science, 345(6193), 216\u2013220. https:\/\/doi.org\/10.1126\/science.1253533","journal-title":"Science"},{"issue":"1","key":"10075_CR29","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/s41467-019-10122-2","volume":"10","author":"YH Cheng","year":"2019","unstructured":"Cheng, Y. H., Chen, Y. C., Lin, E., Brien, R., Jung, S., Chen, Y. T., et al. (2019). Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nature Communications, 10(1), 2163. https:\/\/doi.org\/10.1038\/s41467-019-10122-2","journal-title":"Nature Communications"},{"issue":"1\u20132","key":"10075_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","volume":"176","author":"S Gkountela","year":"2019","unstructured":"Gkountela, S., Castro-Giner, F., Szczerba, B. M., Vetter, M., Landin, J., Scherrer, R., et al. (2019). Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell, 176(1\u20132), 98-112 e114. https:\/\/doi.org\/10.1016\/j.cell.2018.11.046","journal-title":"Cell"},{"issue":"10","key":"10075_CR31","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/2159-8290.CD-18-0432","volume":"8","author":"TT Kwan","year":"2018","unstructured":"Kwan, T. T., Bardia, A., Spring, L. M., Giobbie-Hurder, A., Kalinich, M., Dubash, T., et al. (2018). A digital RNA signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discovery, 8(10), 1286\u20131299. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0432","journal-title":"Cancer Discovery"},{"issue":"7","key":"10075_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel, K., & Alix-Panabieres, C. (2019). Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nature Reviews. Clinical Oncology, 16(7), 409\u2013424. https:\/\/doi.org\/10.1038\/s41571-019-0187-3","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"10","key":"10075_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","volume":"19","author":"L Keller","year":"2019","unstructured":"Keller, L., & Pantel, K. (2019). Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nature Reviews Cancer, 19(10), 553\u2013567. https:\/\/doi.org\/10.1038\/s41568-019-0180-2","journal-title":"Nature Reviews Cancer"},{"issue":"8","key":"10075_CR34","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMoa050434","volume":"353","author":"S Braun","year":"2005","unstructured":"Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., et al. (2005). A pooled analysis of bone marrow micrometastasis in breast cancer. New England Journal of Medicine, 353(8), 793\u2013802. https:\/\/doi.org\/10.1056\/NEJMoa050434","journal-title":"New England Journal of Medicine"},{"key":"10075_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-4939-7144-2_22","volume":"1634","author":"A Soler","year":"2017","unstructured":"Soler, A., Cayrefourcq, L., Mazel, M., & Alix-Panabieres, C. (2017). EpCAM-independent enrichment and detection of viable circulating tumor cells using the EPISPOT assay. Methods in Molecular Biology, 1634, 263\u2013276. https:\/\/doi.org\/10.1007\/978-1-4939-7144-2_22","journal-title":"Methods in Molecular Biology"},{"issue":"9","key":"10075_CR36","doi-asserted-by":"publisher","first-page":"e11908","DOI":"10.15252\/emmm.201911908","volume":"12","author":"C Koch","year":"2020","unstructured":"Koch, C., Kuske, A., Joosse, S. A., Yigit, G., Sflomos, G., Thaler, S., et al. (2020). Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med, 12(9), e11908. https:\/\/doi.org\/10.15252\/emmm.201911908","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10075_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ccell.2017.01.002","volume":"31","author":"A Bardelli","year":"2017","unstructured":"Bardelli, A., & Pantel, K. (2017). Liquid Biopsies, what we do not know (yet). Cancer Cell, 31(2), 172\u2013179. https:\/\/doi.org\/10.1016\/j.ccell.2017.01.002","journal-title":"Cancer Cell"},{"issue":"3","key":"10075_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","volume":"35","author":"AR Thierry","year":"2016","unstructured":"Thierry, A. R., El Messaoudi, S., Gahan, P. B., Anker, P., & Stroun, M. (2016). Origins, structures, and functions of circulating DNA in oncology. Cancer and Metastasis Reviews, 35(3), 347\u2013376. https:\/\/doi.org\/10.1007\/s10555-016-9629-x","journal-title":"Cancer and Metastasis Reviews"},{"key":"10075_CR39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.csbj.2018.10.002","volume":"16","author":"M Elazezy","year":"2018","unstructured":"Elazezy, M., & Joosse, S. A. (2018). Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Computational and Structural Biotechnology Journal, 16, 370\u2013378. https:\/\/doi.org\/10.1016\/j.csbj.2018.10.002","journal-title":"Computational and Structural Biotechnology Journal"},{"issue":"2","key":"10075_CR40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/ijms18020264","volume":"18","author":"JA Vendrell","year":"2017","unstructured":"Vendrell, J. A., Mau-Them, F. T., Beganton, B., Godreuil, S., Coopman, P., & Solassol, J. (2017). Circulating cell free tumor DNA detection as a routine tool for lung cancer patient management. International Journal of Molecular Sciences, 18(2), 264. https:\/\/doi.org\/10.3390\/ijms18020264","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10075_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40246-019-0220-8","volume":"13","author":"M Chen","year":"2019","unstructured":"Chen, M., & Zhao, H. (2019). Next-generation sequencing in liquid biopsy: Cancer screening and early detection. Human Genomics, 13(1), 34. https:\/\/doi.org\/10.1186\/s40246-019-0220-8","journal-title":"Human Genomics"},{"issue":"11","key":"10075_CR42","doi-asserted-by":"publisher","first-page":"e0166354","DOI":"10.1371\/journal.pone.0166354","volume":"11","author":"I Medina Diaz","year":"2016","unstructured":"Medina Diaz, I., Nocon, A., Mehnert, D. H., Fredebohm, J., Diehl, F., & Holtrup, F. (2016). Performance of streck cfDNA blood collection tubes for liquid biopsy testing. PLoS ONE, 11(11), e0166354. https:\/\/doi.org\/10.1371\/journal.pone.0166354","journal-title":"PLoS ONE"},{"issue":"12","key":"10075_CR43","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","volume":"25","author":"P Razavi","year":"2019","unstructured":"Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R., et al. (2019). High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 25(12), 1928\u20131937. https:\/\/doi.org\/10.1038\/s41591-019-0652-7","journal-title":"Nature Medicine"},{"issue":"2","key":"10075_CR44","doi-asserted-by":"publisher","first-page":"e0150197","DOI":"10.1371\/journal.pone.0150197","volume":"11","author":"JL Sherwood","year":"2016","unstructured":"Sherwood, J. L., Corcoran, C., Brown, H., Sharpe, A. D., Musilova, M., & Kohlmann, A. (2016). Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS ONE, 11(2), e0150197. https:\/\/doi.org\/10.1371\/journal.pone.0150197","journal-title":"PLoS ONE"},{"key":"10075_CR45","volume-title":"World cancer report: Cancer Research for Cancer Prevention","year":"2020","unstructured":"Wild, C. P., & W. E., Stewart BW, (Eds.). (2020). World cancer report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer."},{"key":"10075_CR46","doi-asserted-by":"publisher","unstructured":"Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A., et al. (2014). US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst, 106(5), https:\/\/doi.org\/10.1093\/jnci\/dju055","DOI":"10.1093\/jnci\/dju055"},{"issue":"5","key":"10075_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41571-018-0145-5","volume":"16","author":"J Richman","year":"2019","unstructured":"Richman, J., & Dowsett, M. (2019). Beyond 5 years: Enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nature Reviews. Clinical Oncology, 16(5), 296\u2013311. https:\/\/doi.org\/10.1038\/s41571-018-0145-5","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"1","key":"10075_CR48","first-page":"57","volume":"5","author":"GL Smith","year":"2014","unstructured":"Smith, G. L. (2014). The long and short of tamoxifen therapy: A review of the ATLAS Trial. Journal of the Advanced Practitioner in Oncology, 5(1), 57\u201360.","journal-title":"Journal of the Advanced Practitioner in Oncology"},{"issue":"9793","key":"10075_CR49","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative, G, Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., et al. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771\u2013784. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8","journal-title":"Lancet"},{"issue":"9869","key":"10075_CR50","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., et al. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 381(9869), 805\u2013816. https:\/\/doi.org\/10.1016\/S0140-6736(12)61963-1","journal-title":"Lancet"},{"issue":"3","key":"10075_CR51","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/jnci\/djab202","volume":"114","author":"RN Pedersen","year":"2022","unstructured":"Pedersen, R. N., Esen, B. O., Mellemkjaer, L., Christiansen, P., Ejlertsen, B., Lash, T. L., et al. (2022). The incidence of breast cancer recurrence 10\u201332 years after primary diagnosis. Journal of the National Cancer Institute, 114(3), 391\u2013399. https:\/\/doi.org\/10.1093\/jnci\/djab202","journal-title":"Journal of the National Cancer Institute"},{"issue":"19","key":"10075_CR52","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., et al. (2017). 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. New England Journal of Medicine, 377(19), 1836\u20131846. https:\/\/doi.org\/10.1056\/NEJMoa1701830","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10075_CR53","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.21.02062","volume":"40","author":"RN Pedersen","year":"2022","unstructured":"Pedersen, R. N., Mellemkjaer, L., Ejlertsen, B., Norgaard, M., & Cronin-Fenton, D. P. (2022). Mortality after late breast cancer recurrence in Denmark. Journal of Clinical Oncology, 40(13), 1450\u20131463. https:\/\/doi.org\/10.1200\/JCO.21.02062","journal-title":"Journal of Clinical Oncology"},{"issue":"18_suppl","key":"10075_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","volume":"31","author":"RG Gray","year":"2013","unstructured":"Gray, R. G., Rea, D., Handley, K., Bowden, S. J., Perry, P., Earl, H. M., et al. (2013). Journal of Clinical Oncology, 31(18_suppl), 5\u20135. https:\/\/doi.org\/10.1200\/jco.2013.31.18_suppl.5","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10075_CR55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., et al. (2016). Extending aromatase-inhibitor adjuvant therapy to 10 years. New England Journal of Medicine, 375(3), 209\u2013219. https:\/\/doi.org\/10.1056\/NEJMoa1604700","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10075_CR56","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., et al. (2009). Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology, 27(16), 2630\u20132637. https:\/\/doi.org\/10.1200\/JCO.2008.18.8391","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10075_CR57","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/bcr1869","volume":"10","author":"T Fehm","year":"2008","unstructured":"Fehm, T., Muller, V., Alix-Panabieres, C., & Pantel, K. (2008). Micrometastatic spread in breast cancer: Detection, molecular characterization and clinical relevance. Breast Cancer Research, 10(Suppl 1), S1. https:\/\/doi.org\/10.1186\/bcr1869","journal-title":"Breast Cancer Research"},{"issue":"15","key":"10075_CR58","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.ejca.2014.06.025","volume":"50","author":"AD Hartkopf","year":"2014","unstructured":"Hartkopf, A. D., Taran, F. A., Wallwiener, M., Hahn, M., Becker, S., Solomayer, E. F., et al. (2014). Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis. European Journal of Cancer, 50(15), 2550\u20132559. https:\/\/doi.org\/10.1016\/j.ejca.2014.06.025","journal-title":"European Journal of Cancer"},{"key":"10075_CR59","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2021.06.028","volume":"154","author":"AD Hartkopf","year":"2021","unstructured":"Hartkopf, A. D., Brucker, S. Y., Taran, F. A., Harbeck, N., von Au, A., Naume, B., et al. (2021). Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer, 154, 128\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2021.06.028","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10075_CR60","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10549-020-05882-1","volume":"184","author":"P Singh","year":"2020","unstructured":"Singh, P., Tevis, S. E., Hall, C. S., Meas, S., Hwang, R. F., & Lucci, A. (2020). Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score. Breast Cancer Research and Treatment, 184(3), 683\u2013687. https:\/\/doi.org\/10.1007\/s10549-020-05882-1","journal-title":"Breast Cancer Research and Treatment"},{"issue":"2","key":"10075_CR61","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10549-013-2470-9","volume":"138","author":"AD Hartkopf","year":"2013","unstructured":"Hartkopf, A. D., Banys, M., Meier-Stiegen, F., Hahn, M., Rohm, C., Hoffmann, J., et al. (2013). The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse. Breast Cancer Research and Treatment, 138(2), 509\u2013517. https:\/\/doi.org\/10.1007\/s10549-013-2470-9","journal-title":"Breast Cancer Research and Treatment"},{"issue":"10","key":"10075_CR62","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.clon.2008.08.005","volume":"20","author":"E Amir","year":"2008","unstructured":"Amir, E., Ooi, W. S., Simmons, C., Kahn, H., Christakis, M., Popovic, S., et al. (2008). Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies. Clinical Oncology (Royal College of Radiologists), 20(10), 763\u2013768. https:\/\/doi.org\/10.1016\/j.clon.2008.08.005","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"issue":"4","key":"10075_CR63","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000442986","volume":"90","author":"B Rack","year":"2016","unstructured":"Rack, B., Zombirt, E., Trapp, E., Juckstock, J., Andergassen, U., Neugebauer, J., et al. (2016). Comparison of HER2 expression in primary tumor and disseminated tumor cells in the bone marrow of breast cancer patients. Oncology, 90(4), 232\u2013238. https:\/\/doi.org\/10.1159\/000442986","journal-title":"Oncology"},{"issue":"2","key":"10075_CR64","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00404-011-1954-2","volume":"285","author":"B Rack","year":"2012","unstructured":"Rack, B., Juckstock, J., Gunthner-Biller, M., Andergassen, U., Neugebauer, J., Hepp, P., et al. (2012). Trastuzumab clears HER2\/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Archives of Gynecology and Obstetrics, 285(2), 485\u2013492. https:\/\/doi.org\/10.1007\/s00404-011-1954-2","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"10075_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41523-018-0083-5","volume":"4","author":"MJM Magbanua","year":"2018","unstructured":"Magbanua, M. J. M., Rugo, H. S., Hauranieh, L., Roy, R., Scott, J. H., Lee, J. C., et al. (2018). Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer, 4, 31. https:\/\/doi.org\/10.1038\/s41523-018-0083-5","journal-title":"NPJ Breast Cancer"},{"issue":"19","key":"10075_CR66","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-06-0169","volume":"12","author":"M Balic","year":"2006","unstructured":"Balic, M., Lin, H., Young, L., Hawes, D., Giuliano, A., McNamara, G., et al. (2006). Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clinical Cancer Research, 12(19), 5615\u20135621. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0169","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10075_CR67","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc2627","volume":"9","author":"CA Klein","year":"2009","unstructured":"Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews Cancer, 9(4), 302\u2013312. https:\/\/doi.org\/10.1038\/nrc2627","journal-title":"Nature Reviews Cancer"},{"issue":"9","key":"10075_CR68","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.3390\/cancers13092197","volume":"13","author":"JP Capp","year":"2021","unstructured":"Capp, J. P., Nedelcu, A. M., Dujon, A. M., Roche, B., Catania, F., Ujvari, B., et al. (2021). Does cancer biology rely on Parrondo\u2019s principles? Cancers (Basel), 13(9), 2197. https:\/\/doi.org\/10.3390\/cancers13092197","journal-title":"Cancers (Basel)"},{"issue":"23\u201324","key":"10075_CR69","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","volume":"411","author":"MJ Duffy","year":"2010","unstructured":"Duffy, M. J., Evoy, D., & McDermott, E. W. (2010). CA 15\u20133: Uses and limitation as a biomarker for breast cancer. Clinica Chimica Acta, 411(23\u201324), 1869\u20131874. https:\/\/doi.org\/10.1016\/j.cca.2010.08.039","journal-title":"Clinica Chimica Acta"},{"issue":"33","key":"10075_CR70","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","volume":"25","author":"L Harris","year":"2007","unstructured":"Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., et al. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25(33), 5287\u20135312. https:\/\/doi.org\/10.1200\/JCO.2007.14.2364","journal-title":"Journal of Clinical Oncology"},{"issue":"4C","key":"10075_CR71","first-page":"3511","volume":"19","author":"S Lauro","year":"1999","unstructured":"Lauro, S., Trasatti, L., Bordin, F., Lanzetta, G., Bria, E., Gelibter, A., et al. (1999). Comparison of CEA, MCA, CA 15\u20133 and CA 27\u201329 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Research, 19(4C), 3511\u20133515.","journal-title":"Anticancer Research"},{"key":"10075_CR72","doi-asserted-by":"publisher","unstructured":"Rack, B., Schindlbeck, C., Juckstock, J., Andergassen, U., Hepp, P., Zwingers, T., et al. (2014). Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst, 106(5), https:\/\/doi.org\/10.1093\/jnci\/dju066","DOI":"10.1093\/jnci\/dju066"},{"issue":"21","key":"10075_CR73","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1158\/1078-0432.CCR-08-0030","volume":"14","author":"JY Pierga","year":"2008","unstructured":"Pierga, J. Y., Bidard, F. C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., et al. (2008). Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clinical Cancer Research, 14(21), 7004\u20137010. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0030","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10075_CR74","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S1470-2045(12)70209-7","volume":"13","author":"A Lucci","year":"2012","unstructured":"Lucci, A., Hall, C. S., Lodhi, A. K., Bhattacharyya, A., Anderson, A. E., Xiao, L., et al. (2012). Circulating tumour cells in non-metastatic breast cancer: A prospective study. The lancet Oncology, 13(7), 688\u2013695. https:\/\/doi.org\/10.1016\/S1470-2045(12)70209-7","journal-title":"The lancet Oncology"},{"key":"10075_CR75","doi-asserted-by":"publisher","first-page":"130470","DOI":"10.1155\/2013\/130470","volume":"2013","author":"FC Bidard","year":"2013","unstructured":"Bidard, F. C., Belin, L., Delaloge, S., Lerebours, F., Ngo, C., Reyal, F., et al. (2013). Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 Study. Int J Breast Cancer, 2013, 130470. https:\/\/doi.org\/10.1155\/2013\/130470","journal-title":"Int J Breast Cancer"},{"issue":"4","key":"10075_CR76","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/jnci\/djy152","volume":"111","author":"E Trapp","year":"2019","unstructured":"Trapp, E., Janni, W., Schindlbeck, C., Juckstock, J., Andergassen, U., de Gregorio, A., et al. (2019). Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. Journal of the National Cancer Institute, 111(4), 380\u2013387. https:\/\/doi.org\/10.1093\/jnci\/djy152","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10075_CR77","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jamaoncol.2018.2574","volume":"4","author":"J Sparano","year":"2018","unstructured":"Sparano, J., O\u2019Neill, A., Alpaugh, K., Wolff, A. C., Northfelt, D. W., Dang, C. T., et al. (2018). Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncology, 4(12), 1700\u20131706. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2574","journal-title":"JAMA Oncology"},{"issue":"7","key":"10075_CR78","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","volume":"139","author":"MY Kim","year":"2009","unstructured":"Kim, M. Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H., Norton, L., et al. (2009). Tumor self-seeding by circulating cancer cells. Cell, 139(7), 1315\u20131326. https:\/\/doi.org\/10.1016\/j.cell.2009.11.025","journal-title":"Cell"},{"issue":"7917","key":"10075_CR79","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41586-022-04875-y","volume":"607","author":"Z Diamantopoulou","year":"2022","unstructured":"Diamantopoulou, Z., Castro-Giner, F., Schwab, F. D., Foerster, C., Saini, M., Budinjas, S., et al. (2022). The metastatic spread of breast cancer accelerates during sleep. Nature, 607(7917), 156\u2013162. https:\/\/doi.org\/10.1038\/s41586-022-04875-y","journal-title":"Nature"},{"issue":"1","key":"10075_CR80","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13059-020-02179-w","volume":"21","author":"LE Cortes-Hernandez","year":"2020","unstructured":"Cortes-Hernandez, L. E., Eslami, S. Z., Dujon, A. M., Giraudeau, M., Ujvari, B., Thomas, F., et al. (2020). Do malignant cells sleep at night? Genome Biology, 21(1), 276. https:\/\/doi.org\/10.1186\/s13059-020-02179-w","journal-title":"Genome Biology"},{"issue":"8","key":"10075_CR81","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual, J., Attard, G., Bidard, F. C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., et al. (2022). ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group. Annals of Oncology, 33(8), 750\u2013768. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.520","journal-title":"Annals of Oncology"},{"issue":"14","key":"10075_CR82","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","volume":"25","author":"RC Coombes","year":"2019","unstructured":"Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., et al. (2019). Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clinical Cancer Research, 25(14), 4255\u20134263. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3663","journal-title":"Clinical Cancer Research"},{"issue":"13","key":"10075_CR83","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"SJ Dawson","year":"2013","unstructured":"Dawson, S. J., Tsui, D. W., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S. F., et al. (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine, 368(13), 1199\u20131209. https:\/\/doi.org\/10.1056\/NEJMoa1213261","journal-title":"New England Journal of Medicine"},{"issue":"302","key":"10075_CR84","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., et al. (2015). Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science Translational Medicine, 7(302), 302ra133. https:\/\/doi.org\/10.1126\/scitranslmed.aab0021","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10075_CR85","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P. (2019). Epidemiology of prostate cancer. World Journal of Oncology, 10(2), 63\u201389.","journal-title":"World Journal of Oncology"},{"issue":"17","key":"10075_CR86","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D., & Walsh, P. C. (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281(17), 1591\u20131597. https:\/\/doi.org\/10.1001\/jama.281.17.1591","journal-title":"JAMA"},{"issue":"3","key":"10075_CR87","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrc2795","volume":"10","author":"GP Risbridger","year":"2010","unstructured":"Risbridger, G. P., Davis, I. D., Birrell, S. N., & Tilley, W. D. (2010). Breast and prostate cancer: More similar than different. Nature Reviews Cancer, 10(3), 205\u2013212. https:\/\/doi.org\/10.1038\/nrc2795","journal-title":"Nature Reviews Cancer"},{"issue":"9959","key":"10075_CR88","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schroder","year":"2014","unstructured":"Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V., et al. (2014). Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, 384(9959), 2027\u20132035. https:\/\/doi.org\/10.1016\/S0140-6736(14)60525-0","journal-title":"Lancet"},{"issue":"5","key":"10075_CR89","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf, L., Schopfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., et al. (2000). Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Human Pathology, 31(5), 578\u2013583. https:\/\/doi.org\/10.1053\/hp.2000.6698","journal-title":"Human Pathology"},{"issue":"7748","key":"10075_CR90","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","volume":"567","author":"OM Rueda","year":"2019","unstructured":"Rueda, O. M., Sammut, S. J., Seoane, J. A., Chin, S. F., Caswell-Jin, J. L., Callari, M., et al. (2019). Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature, 567(7748), 399\u2013404. https:\/\/doi.org\/10.1038\/s41586-019-1007-8","journal-title":"Nature"},{"issue":"8","key":"10075_CR91","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","volume":"18","author":"LC Hofbauer","year":"2021","unstructured":"Hofbauer, L. C., Bozec, A., Rauner, M., Jakob, F., Perner, S., & Pantel, K. (2021). Novel approaches to target the microenvironment of bone metastasis. Nature Reviews. Clinical Oncology, 18(8), 488\u2013505. https:\/\/doi.org\/10.1038\/s41571-021-00499-9","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"23","key":"10075_CR92","doi-asserted-by":"publisher","first-page":"8672","DOI":"10.1073\/pnas.84.23.8672","volume":"84","author":"G Schlimok","year":"1987","unstructured":"Schlimok, G., Funke, I., Holzmann, B., Gottlinger, G., Schmidt, G., Hauser, H., et al. (1987). Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A, 84(23), 8672\u20138676. https:\/\/doi.org\/10.1073\/pnas.84.23.8672","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10075_CR93","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/0959-8049(95)00290-y","volume":"31A","author":"K Pantel","year":"1995","unstructured":"Pantel, K., Aignherr, C., Kollermann, J., Caprano, J., Riethmuller, G., & Kollermann, M. W. (1995). Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. European Journal of Cancer, 31A(10), 1627\u20131632. https:\/\/doi.org\/10.1016\/0959-8049(95)00290-y","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10075_CR94","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF00431541","volume":"22","author":"R Oberneder","year":"1994","unstructured":"Oberneder, R., Riesenberg, R., Kriegmair, M., Bitzer, U., Klammert, R., Schneede, P., et al. (1994). Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer. Urological Research, 22(1), 3\u20138. https:\/\/doi.org\/10.1007\/BF00431541","journal-title":"Urological Research"},{"issue":"1","key":"10075_CR95","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF00268022","volume":"99","author":"R Riesenberg","year":"1993","unstructured":"Riesenberg, R., Oberneder, R., Kriegmair, M., Epp, M., Bitzer, U., Hofstetter, A., et al. (1993). Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry, 99(1), 61\u201366. https:\/\/doi.org\/10.1007\/BF00268022","journal-title":"Histochemistry"},{"issue":"3","key":"10075_CR96","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/(sici)1097-0142(19980801)83:3<394::aid-cncr2>3.0.co;2-p","volume":"83","author":"SF Slovin","year":"1998","unstructured":"Slovin, S. F., & Scher, H. I. (1998). Detectable tumor cells in the blood and bone marrow: Smoke or fire? Cancer, 83(3), 394\u2013398. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19980801)83:3%3c394::aid-cncr2%3e3.0.co;2-p","journal-title":"Cancer"},{"issue":"3","key":"10075_CR97","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/(SICI)1097-0142(19980801)83:3<538::AID-CNCR23>3.0.CO;2-W","volume":"83","author":"P Mueller","year":"1998","unstructured":"Mueller, P., Carroll, P., Bowers, E., Moore, D., 2nd., Cher, M., Presti, J., et al. (1998). Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer, 83(3), 538\u2013546.","journal-title":"Cancer"},{"issue":"14","key":"10075_CR98","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1158\/0008-5472.CAN-08-0812","volume":"68","author":"IN Holcomb","year":"2008","unstructured":"Holcomb, I. N., Grove, D. I., Kinnunen, M., Friedman, C. L., Gallaher, I. S., Morgan, T. M., et al. (2008). Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Research, 68(14), 5599\u20135608. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0812","journal-title":"Cancer Research"},{"issue":"24","key":"10075_CR99","doi-asserted-by":"publisher","first-page":"7383","DOI":"10.1158\/0008-5472.CAN-14-0934","volume":"74","author":"M Guzvic","year":"2014","unstructured":"Guzvic, M., Braun, B., Ganzer, R., Burger, M., Nerlich, M., Winkler, S., et al. (2014). Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes. Cancer Research, 74(24), 7383\u20137394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0934","journal-title":"Cancer Research"},{"issue":"20","key":"10075_CR100","doi-asserted-by":"publisher","first-page":"9939","DOI":"10.18632\/oncotarget.2480","volume":"5","author":"L Chery","year":"2014","unstructured":"Chery, L., Lam, H. M., Coleman, I., Lakely, B., Coleman, R., Larson, S., et al. (2014). Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget, 5(20), 9939\u20139951. https:\/\/doi.org\/10.18632\/oncotarget.2480","journal-title":"Oncotarget"},{"issue":"8","key":"10075_CR101","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/ijc.22488","volume":"120","author":"A Berg","year":"2007","unstructured":"Berg, A., Berner, A., Lilleby, W., Bruland, O. S., Fossa, S. D., Nesland, J. M., et al. (2007). Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. International Journal of Cancer, 120(8), 1603\u20131609. https:\/\/doi.org\/10.1002\/ijc.22488","journal-title":"International Journal of Cancer"},{"issue":"30","key":"10075_CR102","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.1200\/JCO.2007.15.0441","volume":"26","author":"J Kollermann","year":"2008","unstructured":"Kollermann, J., Weikert, S., Schostak, M., Kempkensteffen, C., Kleinschmidt, K., Rau, T., et al. (2008). Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. Journal of Clinical Oncology, 26(30), 4928\u20134933. https:\/\/doi.org\/10.1200\/JCO.2007.15.0441","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10075_CR103","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1158\/1078-0432.CCR-08-1754","volume":"15","author":"TM Morgan","year":"2009","unstructured":"Morgan, T. M., Lange, P. H., Porter, M. P., Lin, D. W., Ellis, W. J., Gallaher, I. S., et al. (2009). Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clinical Cancer Research, 15(2), 677\u2013683. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1754","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10075_CR104","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1200\/JCO.2008.17.0563","volume":"27","author":"D Weckermann","year":"2009","unstructured":"Weckermann, D., Polzer, B., Ragg, T., Blana, A., Schlimok, G., Arnholdt, H., et al. (2009). Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. Journal of Clinical Oncology, 27(10), 1549\u20131556. https:\/\/doi.org\/10.1200\/JCO.2008.17.0563","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10075_CR105","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ijc.28002","volume":"133","author":"W Lilleby","year":"2013","unstructured":"Lilleby, W., Stensvold, A., Mills, I. G., & Nesland, J. M. (2013). Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients. International Journal of Cancer, 133(1), 149\u2013155. https:\/\/doi.org\/10.1002\/ijc.28002","journal-title":"International Journal of Cancer"},{"issue":"6","key":"10075_CR106","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/pros.22947","volume":"75","author":"T Todenhofer","year":"2015","unstructured":"Todenhofer, T., Hennenlotter, J., Faber, F., Wallwiener, D., Schilling, D., Kuhs, U., et al. (2015). Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer. Prostate, 75(6), 637\u2013645. https:\/\/doi.org\/10.1002\/pros.22947","journal-title":"Prostate"},{"issue":"10","key":"10075_CR107","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/JCO.2008.21.2092","volume":"27","author":"HI Scher","year":"2009","unstructured":"Scher, H. I., & Pantel, K. (2009). Bone marrow aspiration for disseminated tumor cell detection: A must-have test or is the jury still out? Journal of Clinical Oncology, 27(10), 1531\u20131533. https:\/\/doi.org\/10.1200\/JCO.2008.21.2092","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10075_CR108","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.juro.2018.01.033","volume":"199","author":"HJ Chalfin","year":"2018","unstructured":"Chalfin, H. J., Glavaris, S. A., Malihi, P. D., Sperger, J. M., Gorin, M. A., Lu, C., et al. (2018). Prostate cancer disseminated tumor cells are rarely detected in the bone marrow of patients with localized disease undergoing radical prostatectomy across multiple rare cell detection platforms. Journal of Urology, 199(6), 1494\u20131501. https:\/\/doi.org\/10.1016\/j.juro.2018.01.033","journal-title":"Journal of Urology"},{"issue":"1","key":"10075_CR109","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1373\/clinchem.2018.287102","volume":"65","author":"K Pantel","year":"2019","unstructured":"Pantel, K., Hille, C., & Scher, H. I. (2019). Circulating tumor cells in prostate cancer: From discovery to clinical utility. Clinical Chemistry, 65(1), 87\u201399. https:\/\/doi.org\/10.1373\/clinchem.2018.287102","journal-title":"Clinical Chemistry"},{"issue":"23","key":"10075_CR110","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","volume":"13","author":"DC Danila","year":"2007","unstructured":"Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., et al. (2007). Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical Cancer Research, 13(23), 7053\u20137058. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1506","journal-title":"Clinical Cancer Research"},{"issue":"19","key":"10075_CR111","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","volume":"14","author":"JS de Bono","year":"2008","unstructured":"de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14(19), 6302\u20136309. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0872","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10075_CR112","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","volume":"13","author":"S Riethdorf","year":"2007","unstructured":"Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the Cell Search system. Clinical Cancer Research, 13(3), 920\u2013928. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1695","journal-title":"Clinical Cancer Research"},{"key":"10075_CR113","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.euros.2021.09.017","volume":"34","author":"S Knipper","year":"2021","unstructured":"Knipper, S., Riethdorf, S., Werner, S., Tilki, D., Graefen, M., Pantel, K., et al. (2021). Possible role of circulating tumour cells for prediction of salvage lymph node dissection outcome in patients with early prostate cancer recurrence. Eur Urol Open Sci, 34, 55\u201358. https:\/\/doi.org\/10.1016\/j.euros.2021.09.017","journal-title":"Eur Urol Open Sci"},{"issue":"7","key":"10075_CR114","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/cancers11070933","volume":"11","author":"S Chen","year":"2019","unstructured":"Chen, S., Tauber, G., Langsenlehner, T., Schmolzer, L. M., Potscher, M., Riethdorf, S., et al. (2019). In vivo detection of circulating tumor cells in high-risk non-metastatic prostate cancer patients undergoing radiotherapy. Cancers (Basel), 11(7), 933. https:\/\/doi.org\/10.3390\/cancers11070933","journal-title":"Cancers (Basel)"},{"key":"10075_CR115","doi-asserted-by":"publisher","first-page":"39736","DOI":"10.1038\/srep39736","volume":"6","author":"A Kuske","year":"2016","unstructured":"Kuske, A., Gorges, T. M., Tennstedt, P., Tiebel, A. K., Pompe, R., Preisser, F., et al. (2016). Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Science and Reports, 6, 39736. https:\/\/doi.org\/10.1038\/srep39736","journal-title":"Science and Reports"},{"issue":"6","key":"10075_CR116","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/cancers11060802","volume":"11","author":"J Budna-Tukan","year":"2019","unstructured":"Budna-Tukan, J., Swierczewska, M., Mazel, M., Cieslikowski, W. A., Ida, A., Jankowiak, A., et al. (2019). Analysis of circulating tumor cells in patients with non-metastatic high-risk prostate cancer before and after radiotherapy using three different enumeration assays. Cancers (Basel), 11(6), 802. https:\/\/doi.org\/10.3390\/cancers11060802","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10075_CR117","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/cancers12010160","volume":"12","author":"WA Cieslikowski","year":"2020","unstructured":"Cieslikowski, W. A., Budna-Tukan, J., Swierczewska, M., Ida, A., Hrab, M., Jankowiak, A., et al. (2020). Circulating tumor cells as a marker of disseminated disease in patients with newly diagnosed high-risk prostate cancer. Cancers (Basel), 12(1), 160. https:\/\/doi.org\/10.3390\/cancers12010160","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10075_CR118","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41585-018-0119-5","volume":"16","author":"EE van der Toom","year":"2019","unstructured":"van der Toom, E. E., Axelrod, H. D., de la Rosette, J. J., de Reijke, T. M., Pienta, K. J., & Valkenburg, K. C. (2019). Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nature Reviews. Urology, 16(1), 7\u201322. https:\/\/doi.org\/10.1038\/s41585-018-0119-5","journal-title":"Nature Reviews. Urology"},{"issue":"11","key":"10075_CR119","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1373\/clinchem.2016.260299","volume":"62","author":"TM Gorges","year":"2016","unstructured":"Gorges, T. M., Kuske, A., Rock, K., Mauermann, O., Muller, V., Peine, S., et al. (2016). Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells. Clinical Chemistry, 62(11), 1504\u20131515. https:\/\/doi.org\/10.1373\/clinchem.2016.260299","journal-title":"Clinical Chemistry"},{"key":"10075_CR120","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3332\/ecancer.2019.934","volume":"13","author":"NP Murray","year":"2019","unstructured":"Murray, N. P., Aedo, S., Fuentealba, C., Reyes, E., Salazar, A., Lopez, M. A., et al. (2019). Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy. Ecancermedicalscience, 13, 934. https:\/\/doi.org\/10.3332\/ecancer.2019.934","journal-title":"Ecancermedicalscience"},{"issue":"6","key":"10075_CR121","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/1878-0261.12978","volume":"15","author":"E Lianidou","year":"2021","unstructured":"Lianidou, E. (2021). Detection and relevance of epigenetic markers on ctDNA: Recent advances and future outlook. Molecular Oncology, 15(6), 1683\u20131700. https:\/\/doi.org\/10.1002\/1878-0261.12978","journal-title":"Molecular Oncology"},{"issue":"4","key":"10075_CR122","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/1878-0261.12183","volume":"12","author":"C Haldrup","year":"2018","unstructured":"Haldrup, C., Pedersen, A. L., Ogaard, N., Strand, S. H., Hoyer, S., Borre, M., et al. (2018). Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. Molecular Oncology, 12(4), 545\u2013560. https:\/\/doi.org\/10.1002\/1878-0261.12183","journal-title":"Molecular Oncology"},{"issue":"4","key":"10075_CR123","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","volume":"32","author":"W Yu","year":"2021","unstructured":"Yu, W., Hurley, J., Roberts, D., Chakrabortty, S. K., Enderle, D., Noerholm, M., et al. (2021). Exosome-based liquid biopsies in cancer: Opportunities and challenges. Annals of Oncology, 32(4), 466\u2013477. https:\/\/doi.org\/10.1016\/j.annonc.2021.01.074","journal-title":"Annals of Oncology"},{"issue":"12","key":"10075_CR124","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","volume":"11","author":"EJ Moding","year":"2021","unstructured":"Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021). Detecting liquid remnants of solid tumors: Circulating tumor DNA minimal residual disease. Cancer Discovery, 11(12), 2968\u20132986. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0634","journal-title":"Cancer Discovery"},{"issue":"7","key":"10075_CR125","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/jamaoncol.2022.0511","volume":"8","author":"T Jun","year":"2022","unstructured":"Jun, T., & Oh, W. K. (2022). Does circulating tumor DNA measure up to prostate-specific antigen? JAMA Oncology, 8(7), 972\u2013974. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0511","journal-title":"JAMA Oncology"},{"issue":"9","key":"10075_CR126","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.3390\/cancers12092354","volume":"12","author":"P Hellmund","year":"2020","unstructured":"Hellmund, P., Schmitt, J., Roessler, M., Meier, F., & Schoffer, O. (2020). Targeted and checkpoint inhibitor therapy of metastatic malignant melanoma in Germany, 2000\u20132016. Cancers (Basel), 12(9), 2354. https:\/\/doi.org\/10.3390\/cancers12092354","journal-title":"Cancers (Basel)"},{"key":"10075_CR127","doi-asserted-by":"publisher","unstructured":"Koch-Institut, R., & e.V., G. d. e. K. i. D. (2019). Krebs in Deutschland 2015\/2016. https:\/\/doi.org\/10.25646\/5977","DOI":"10.25646\/5977"},{"issue":"8","key":"10075_CR128","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","volume":"25","author":"JE Gershenwald","year":"2018","unstructured":"Gershenwald, J. E., & Scolyer, R. A. (2018). Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Annals of Surgical Oncology, 25(8), 2105\u20132110. https:\/\/doi.org\/10.1245\/s10434-018-6513-7","journal-title":"Annals of Surgical Oncology"},{"issue":"8","key":"10075_CR129","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/biom11081213","volume":"11","author":"C D'Arcy","year":"2021","unstructured":"D\u2019Arcy, C., & Kiel, C. (2021). Cell adhesion molecules in normal skin and melanoma. Biomolecules, 11(8), 1213. https:\/\/doi.org\/10.3390\/biom11081213","journal-title":"Biomolecules"},{"issue":"1","key":"10075_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2004.08.007","volume":"218","author":"S North","year":"2005","unstructured":"North, S., Moenner, M., & Bikfalvi, A. (2005). Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Letters, 218(1), 1\u201314. https:\/\/doi.org\/10.1016\/j.canlet.2004.08.007","journal-title":"Cancer Letters"},{"issue":"8","key":"10075_CR131","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 8(8), 592\u2013603. https:\/\/doi.org\/10.1038\/nrc2442","journal-title":"Nature Reviews Cancer"},{"key":"10075_CR132","doi-asserted-by":"publisher","unstructured":"Szeimies, R., Hauschild, A., Garbe, C., Kaufmann, R., & Landthaler, M.\u00a0(2009).\u00a0Tumoren der Haut. 1. edition. Stuttgart: Thieme. https:\/\/doi.org\/10.1055\/b-002-37780","DOI":"10.1055\/b-002-37780"},{"issue":"33","key":"10075_CR133","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., et al. (2020). Longer Follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III Mmelanoma: Updated results from the EORTC 1325-MG\/KEYNOTE-054 Trial. Journal of Clinical Oncology, 38(33), 3925\u20133936. https:\/\/doi.org\/10.1200\/JCO.20.02110","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10075_CR134","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","volume":"31","author":"CN Owen","year":"2020","unstructured":"Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., et al. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy(). Annals of Oncology, 31(8), 1075\u20131082. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.471","journal-title":"Annals of Oncology"},{"issue":"4","key":"10075_CR135","doi-asserted-by":"publisher","first-page":"MMT32","DOI":"10.2217\/mmt-2019-0016","volume":"6","author":"D Grossman","year":"2019","unstructured":"Grossman, D., Kim, C. C., Hartman, R. I., Berry, E., Nelson, K. C., Okwundu, N., et al. (2019). Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma Management, 6(4), MMT32. https:\/\/doi.org\/10.2217\/mmt-2019-0016","journal-title":"Melanoma Management"},{"issue":"7","key":"10075_CR136","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/ijd.15594","volume":"60","author":"A Yousaf","year":"2021","unstructured":"Yousaf, A., Tjien-Fooh, F. J., Rentroia-Pacheco, B., Quattrocchi, E., Kobic, A., Tempel, D., et al. (2021). Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study. Intenational Journal of Dermatology, 60(7), 851\u2013856. https:\/\/doi.org\/10.1111\/ijd.15594","journal-title":"Intenational Journal of Dermatology"},{"key":"10075_CR137","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","volume":"18","author":"EZ Keung","year":"2018","unstructured":"Keung, E. Z., & Gershenwald, J. E. (2018). The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Review of Anticancer Therapy, 18, 775\u2013784. https:\/\/doi.org\/10.1080\/14737140.2018.1489246","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"15_suppl","key":"10075_CR138","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","volume":"39","author":"JD Wolchok","year":"2021","unstructured":"Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., et al. (2021). CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. Journal of Clinical Oncology, 39(15_suppl), 9506\u20139506. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9506","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10075_CR139","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher, K. N., Guise, T. A., & McCauley, L. K. (2011). Cancer to bone: A fatal attraction. Nature Reviews Cancer, 11(6), 411\u2013425. https:\/\/doi.org\/10.1038\/nrc3055","journal-title":"Nature Reviews Cancer"},{"issue":"6","key":"10075_CR140","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/cells8060627","volume":"8","author":"O Chernysheva","year":"2019","unstructured":"Chernysheva, O., Markina, I., Demidov, L., Kupryshina, N., Chulkova, S., Palladina, A., et al. (2019). Bone marrow involvement in melanoma. potentials for detection of disseminated tumor cells and characterization of their subsets by flow cytometry. Cells, 8(6), 627. https:\/\/doi.org\/10.3390\/cells8060627","journal-title":"Cells"},{"key":"10075_CR141","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2020.01.016","volume":"474","author":"F Flores-Guzman","year":"2020","unstructured":"Flores-Guzman, F., Utikal, J., & Umansky, V. (2020). Dormant tumor cells interact with memory CD8(+) T cells in RET transgenic mouse melanoma model. Cancer Letters, 474, 74\u201381. https:\/\/doi.org\/10.1016\/j.canlet.2020.01.016","journal-title":"Cancer Letters"},{"issue":"10240","key":"10075_CR142","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., et al. (2020). Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 395(10240), 1835\u20131844. https:\/\/doi.org\/10.1016\/S0140-6736(20)30934-X","journal-title":"Lancet"},{"issue":"2","key":"10075_CR143","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/oxfordjournals.annonc.a010544","volume":"7","author":"P Fumoleau","year":"1996","unstructured":"Fumoleau, P., Chevallier, B., Kerbrat, P., Krakowski, Y., Misset, J. L., Maugard-Louboutin, C., et al. (1996). A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Annals of Oncology, 7(2), 165\u2013171. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a010544","journal-title":"Annals of Oncology"},{"issue":"3","key":"10075_CR144","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ijc.33217","volume":"148","author":"I Heidrich","year":"2021","unstructured":"Heidrich, I., Ackar, L., Mossahebi Mohammadi, P., & Pantel, K. (2021). Liquid biopsies: Potential and challenges. International Journal of Cancer, 148(3), 528\u2013545. https:\/\/doi.org\/10.1002\/ijc.33217","journal-title":"International Journal of Cancer"},{"key":"10075_CR145","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","volume":"136","author":"M Kuske","year":"2018","unstructured":"Kuske, M., Westphal, D., Wehner, R., Schmitz, M., Beissert, S., Praetorius, C., et al. (2018). Immunomodulatory effects of BRAF and MEK inhibitors: Implications for melanoma therapy. Pharmacological Research, 136, 151\u2013159. https:\/\/doi.org\/10.1016\/j.phrs.2018.08.019","journal-title":"Pharmacological Research"},{"key":"10075_CR146","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/PO.19.00174","volume":"4","author":"J Braune","year":"2020","unstructured":"Braune, J., Keller, L., Schiller, F., Graf, E., Rafei-Shamsabadi, D., Wehrle, J., et al. (2020). Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma. JCO Precision Oncology, 4, 20\u201331. https:\/\/doi.org\/10.1200\/PO.19.00174","journal-title":"JCO Precision Oncology"},{"issue":"3","key":"10075_CR147","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","volume":"22","author":"MM Syeda","year":"2021","unstructured":"Syeda, M. M., Wiggins, J. M., Corless, B. C., Long, G. V., Flaherty, K. T., Schadendorf, D., et al. (2021). Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: A clinical validation study. The Lancet Oncology, 22(3), 370\u2013380. https:\/\/doi.org\/10.1016\/S1470-2045(20)30726-9","journal-title":"The Lancet Oncology"},{"issue":"5","key":"10075_CR148","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/annonc\/mdz075","volume":"30","author":"JH Lee","year":"2019","unstructured":"Lee, J. H., Saw, R. P., Thompson, J. F., Lo, S., Spillane, A. J., Shannon, K. F., et al. (2019). Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology, 30(5), 815\u2013822. https:\/\/doi.org\/10.1093\/annonc\/mdz075","journal-title":"Annals of Oncology"},{"issue":"11","key":"10075_CR149","doi-asserted-by":"publisher","first-page":"107765","DOI":"10.1016\/j.celrep.2020.107765","volume":"31","author":"X Li","year":"2020","unstructured":"Li, X., Karras, P., Torres, R., Rambow, F., van den Oord, J., Marine, J. C., et al. (2020). Disseminated melanoma cells transdifferentiate into endothelial cells in intravascular niches at metastatic sites. Cell Reports, 31(11), 107765. https:\/\/doi.org\/10.1016\/j.celrep.2020.107765","journal-title":"Cell Reports"},{"issue":"11","key":"10075_CR150","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3390\/cancers11111685","volume":"11","author":"K Gorges","year":"2019","unstructured":"Gorges, K., Wiltfang, L., Gorges, T. M., Sartori, A., Hildebrandt, L., Keller, L., et al. (2019). Intra-patient heterogeneity of circulating tumor cells and circulating tumor DNA in blood of melanoma patients. Cancers (Basel), 11(11), 1685. https:\/\/doi.org\/10.3390\/cancers11111685","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10075_CR151","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdz048","volume":"30","author":"L Tan","year":"2019","unstructured":"Tan, L., Sandhu, S., Lee, R. J., Li, J., Callahan, J., Ftouni, S., et al. (2019). Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Annals of Oncology, 30(5), 804\u2013814. https:\/\/doi.org\/10.1093\/annonc\/mdz048","journal-title":"Annals of Oncology"},{"issue":"5","key":"10075_CR152","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., et al. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 28(5), 1130\u20131136. https:\/\/doi.org\/10.1093\/annonc\/mdx026","journal-title":"Annals of Oncology"},{"issue":"1","key":"10075_CR153","doi-asserted-by":"publisher","first-page":"18682","DOI":"10.1038\/s41598-020-75792-1","volume":"10","author":"GT Marczynski","year":"2020","unstructured":"Marczynski, G. T., Laus, A. C., Dos Reis, M. B., Reis, R. M., & Vazquez, V. L. (2020). Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. Science and Reports, 10(1), 18682. https:\/\/doi.org\/10.1038\/s41598-020-75792-1","journal-title":"Science and Reports"},{"key":"10075_CR154","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fonc.2018.00381","volume":"8","author":"K Weidenfeld","year":"2018","unstructured":"Weidenfeld, K., & Barkan, D. (2018). EMT and stemness in tumor dormancy and outgrowth: Are they intertwined processes? Frontiers in Oncology, 8, 381. https:\/\/doi.org\/10.3389\/fonc.2018.00381","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10075_CR155","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1186\/s12885-022-09829-1","volume":"22","author":"C Felici","year":"2022","unstructured":"Felici, C., Mannavola, F., Stucci, L. S., Duda, L., Cafforio, P., Porta, C., et al. (2022). Circulating tumor cells from melanoma patients show phenotypic plasticity and metastatic potential in xenograft NO.DCB17 mice. BMC Cancer, 22(1), 754. https:\/\/doi.org\/10.1186\/s12885-022-09829-1","journal-title":"BMC Cancer"},{"issue":"6","key":"10075_CR156","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1200\/JCO.2005.04.098","volume":"23","author":"C Voit","year":"2005","unstructured":"Voit, C., Kron, M., Rademaker, J., Schwurzer-Voit, M., Sterry, W., Weber, L., et al. (2005). Molecular staging in stage II and III melanoma patients and its effect on long-term survival. Journal of Clinical Oncology, 23(6), 1218\u20131227. https:\/\/doi.org\/10.1200\/JCO.2005.04.098","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10075_CR157","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-19-2670","volume":"26","author":"A Lucci","year":"2020","unstructured":"Lucci, A., Hall, C. S., Patel, S. P., Narendran, B., Bauldry, J. B., Royal, R. E., et al. (2020). Circulating tumor cells and early relapse in node-positive melanoma. Clinical Cancer Research, 26(8), 1886\u20131895. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2670","journal-title":"Clinical Cancer Research"},{"issue":"31","key":"10075_CR158","doi-asserted-by":"publisher","first-page":"8057","DOI":"10.1200\/JCO.2005.02.0958","volume":"23","author":"K Koyanagi","year":"2005","unstructured":"Koyanagi, K., O\u2019Day, S. J., Gonzalez, R., Lewis, K., Robinson, W. A., Amatruda, T. T., et al. (2005). Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: Outcome prediction in a multicenter trial. Journal of Clinical Oncology, 23(31), 8057\u20138064. https:\/\/doi.org\/10.1200\/JCO.2005.02.0958","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10075_CR159","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12885-021-08016-y","volume":"21","author":"Y Kiniwa","year":"2021","unstructured":"Kiniwa, Y., Nakamura, K., Mikoshiba, A., Ashida, A., Akiyama, Y., Morimoto, A., et al. (2021). Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation. BMC Cancer, 21(1), 287. https:\/\/doi.org\/10.1186\/s12885-021-08016-y","journal-title":"BMC Cancer"},{"issue":"18","key":"10075_CR160","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1158\/0008-5472.CAN-18-0644","volume":"78","author":"M Vishnoi","year":"2018","unstructured":"Vishnoi, M., Boral, D., Liu, H., Sprouse, M. L., Yin, W., Goswami-Sewell, D., et al. (2018). Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs. Cancer Research, 78(18), 5349\u20135362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0644","journal-title":"Cancer Research"},{"issue":"2","key":"10075_CR161","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1158\/1535-7163.MCT-18-0584","volume":"18","author":"MA Papadaki","year":"2019","unstructured":"Papadaki, M. A., Stoupis, G., Theodoropoulos, P. A., Mavroudis, D., Georgoulias, V., & Agelaki, S. (2019). Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Molecular Cancer Therapeutics, 18(2), 437\u2013447. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0584","journal-title":"Molecular Cancer Therapeutics"},{"issue":"11","key":"10075_CR162","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto, P. A., Del Vecchio, M., Mandala, M., Gogas, H., Arance, A. M., Dalle, S., et al. (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The lancet Oncology, 21(11), 1465\u20131477. https:\/\/doi.org\/10.1016\/S1470-2045(20)30494-0","journal-title":"The lancet Oncology"},{"issue":"3","key":"10075_CR163","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","volume":"21","author":"R Dummer","year":"2020","unstructured":"Dummer, R., Brase, J. C., Garrett, J., Campbell, C. D., Gasal, E., Squires, M., et al. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): Exploratory biomarker analyses from a randomised, phase 3 trial. The lancet Oncology, 21(3), 358\u2013372. https:\/\/doi.org\/10.1016\/S1470-2045(20)30062-0","journal-title":"The lancet Oncology"},{"key":"10075_CR164","doi-asserted-by":"publisher","unstructured":"Lampignano, R., Neumann, M., Weber, S., Kloten, V., Herdean, A., Voss, T., Groelz, D., Babayan, A., Tibbesma, M., Schlumpberger, M., Chemi, F., Rothwell, D. G., Wikman, H., Galizzi, J. P., Riise Bergheim, I., Russnes, H., Mussolin, B., Bonin, S., Voigt, C., Musa, H., \u2026 Heitzer, E. (2020). Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows.\u00a0Clinical Chemistry,\u00a066(1), 149\u2013160. https:\/\/doi.org\/10.1373\/clinchem.2019.306837","DOI":"10.1373\/clinchem.2019.306837"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-022-10075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-022-10075-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-022-10075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T03:21:12Z","timestamp":1678764072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-022-10075-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":164,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10075"],"URL":"https:\/\/doi.org\/10.1007\/s10555-022-10075-x","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors do not declare any conflict of interest that are directly or indirectly related to this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}